CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work and can afford the risks. Trading CFDs is high risk and is not suitable for everyone. Refer to our PDS and Target Market Determination. AFSL 513393
Open platformOpen platform

AirSculpt misses Q3 revenue estimates, cuts outlook

By Reuters News


Overview

  • US body contouring procedures provider's Q3 revenue fell 8.7%, missing analysts' expectations

  • Adjusted loss per share was larger than expected, while adjusted EBITDA missed estimates

  • Company cut 2026 revenue and adjusted EBITDA guidance after Q3 underperformance


Outlook

  • AirSculpt cuts 2026 revenue outlook to $144 mln-$146 mln from $151 mln-$157 mln

  • Company lowers 2026 adjusted EBITDA guidance to $9 mln-$10 mln from $12 mln-$14 mln

  • Company expects third quarter performance trends to continue through year-end


Result Drivers

  • CASE VOLUME DECLINE - Co said lower case volume contributed to revenue decline

  • GLP-1 PROCEDURES - Co said expansion of GLP-1-related procedures represented about 10% of total cases in Q3


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Revenue

Miss

$31.94 mln

$34.44 mln (4 Analysts)

Q3 Adjusted Loss Per Share

Miss

$0.08

$0.05 (4 Analysts)

Q3 Net Loss

$7.2 mln

Q3 Adjusted EBITDA

Miss

$400,000

$1.67 mln (3 Analysts)


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the healthcare facilities & services peer group is "buy"

  • Wall Street's median 12-month price target for AirSculpt Technologies Inc is $3.00, about 108.3% above its November 5 closing price of $1.44


Reuters Recommended Reads

  • Nov 4 - Evolus Q3 revenue rises 13% on toxin and HA gel growth

  • Nov 6 - Lilly to sell obesity drugs directly on Hims & Hers site

  • Nov 3 - Rhythm Pharma Q3 net loss narrower than estimated on IMCIVREE demand


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.